Oppenheimer Asset Management Inc. Acquires Shares of 631,501 Pfizer, Inc. (PFE)

Oppenheimer Asset Management Inc. acquired a new stake in Pfizer, Inc. (NYSE:PFE) during the first quarter, Holdings Channel reports. The institutional investor acquired 631,501 shares of the biopharmaceutical company’s stock, valued at approximately $21,605,000. Pfizer comprises 0.6% of Oppenheimer Asset Management Inc.’s investment portfolio, making the stock its 25th largest position.

Other large investors also recently made changes to their positions in the company. Logan Capital Management Inc. increased its stake in shares of Pfizer by 3.3% in the first quarter. Logan Capital Management Inc. now owns 505,578 shares of the biopharmaceutical company’s stock valued at $17,296,000 after buying an additional 16,001 shares during the last quarter. Edmond DE Rothschild Holding S.A. increased its stake in shares of Pfizer by 2.6% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 3,048,969 shares of the biopharmaceutical company’s stock valued at $104,305,000 after buying an additional 76,594 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock valued at $1,069,433,000 after buying an additional 377,404 shares during the last quarter. Brown Advisory Securities LLC increased its stake in shares of Pfizer by 6.8% in the first quarter. Brown Advisory Securities LLC now owns 60,015 shares of the biopharmaceutical company’s stock valued at $2,054,000 after buying an additional 3,825 shares during the last quarter. Finally, Good Life Advisors LLC increased its stake in shares of Pfizer by 24.7% in the first quarter. Good Life Advisors LLC now owns 18,348 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 3,629 shares during the last quarter. Institutional investors and hedge funds own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) traded up 0.3217% on Friday, hitting $33.5275. The company’s stock had a trading volume of 3,556,221 shares. The stock’s 50-day moving average price is $33.43 and its 200-day moving average price is $33.30. The firm has a market cap of $200.09 billion, a price-to-earnings ratio of 24.5263 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. Pfizer’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. Equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.83%. Pfizer’s dividend payout ratio is presently 94.12%.

TRADEMARK VIOLATION WARNING: “Oppenheimer Asset Management Inc. Acquires Shares of 631,501 Pfizer, Inc. (PFE)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.com-unik.info/2017/08/11/oppenheimer-asset-management-inc-acquires-shares-of-631501-pfizer-inc-pfe.html.

Several brokerages have recently issued reports on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Finally, UBS AG restated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $37.77.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit